학술논문
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
Document Type
article
Author
Yutaka Shimazu; Junya Kanda; Satoru Kosugi; Tomoki Ito; Hitomi Kaneko; Kazunori Imada; Yuji Shimura; Shin-ichi Fuchida; Kentaro Fukushima; Hirokazu Tanaka; Satoshi Yoshihara; Kensuke Ohta; Nobuhiko Uoshima; Hideo Yagi; Hirohiko Shibayama; Ryosuke Yamamura; Yasuhiro Tanaka; Hitoji Uchiyama; Yoshiyuki Onda; Yoko Adachi; Hitoshi Hanamoto; Ryoichi Takahashi; Mitsuhiro Matsuda; Takashi Miyoshi; Teruhito Takakuwa; Masayuki Hino; Naoki Hosen; Shosaku Nomura; Chihiro Shimazaki; Itaru Matsumura; Akifumi Takaori-Kondo; Junya Kuroda
Source
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Subject
Language
English
ISSN
2045-2322
Abstract
Abstract Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients who underwent 201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% confidence interval was 6.29 months (5.18–9.20) in this cohort. Univariate analysis showed that patients with any of the following had longer TTNT: no high risk cytogenic abnormalities, more white blood cells, more lymphocytes, non-deviated κ/λ ratio, lower β2 microglobulin levels (B2MG), fewer prior drug regimens, no prior daratumumab use and better response after elotuzumab treatment. A multivariate analysis showed that TTNT was longer in patients with more lymphocytes (≥ 1400/μL), non-deviated κ/λ ratio (0.1–10), lower B2MG (